Clinical Trial Update: A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability study of CP-690,550 (tofacitinib) in adults with moderate-to-severe chronic plaque psoriasis was terminated. Results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: TERMINATED | Results posted: 2017-06-26